Extravasation/Infiltration Management Chart
CARBOplatin X € With or without pain Carmustine X € Cool to touch CISplatin* X X € Edema <1" in any direction Cladribine X X € Skin blanched Cyclophosphamide X X € With or without pain Cytarabine X X € Cool to touch Dacarbazine X € Edema 1-6" in any direction Dactinomycin* X € Skin blanched, translucent DAUNorubicin* X X €
Download Extravasation/Infiltration Management Chart
Information
Domain:
Source:
Link to this page:
Documents from same domain
Pediatric Pharmacy Inpatient Care Programs
pedsrx.johnshopkins.eduThe Pediatric Pharmacy Inpatient Programs are managed by our Pediatric Clinical Pharmacy Specialists ... & Cardiology/Heart Transplant Cell: (609) 937 – 6202 1. Call Cell 2. CORUS ... inpatient anticoagulation requires pharmacists to complete a warfarin competency, followed by evaluation. ...
Parenteral Nutrition Recommendations for Pediatric Patients
pedsrx.johnshopkins.eduJul 13, 2018 · July 13, 2018 . PN Additives Indications for Use Dosing Trace Elements All patients, unless direct hyperbilirubinemia or otherwise indicated. Auto defaults in EPIC to weight based dosing. You will need to modify dosing if hyperbilirubinemia (Dbili >2).
Related documents
POTENTIAL IRRITANT MEDICATIONS
mi-hms.orgPOTENTIAL IRRITANT MEDICATIONS * (Consider administration via central venous catheter – should not administer via Midline) *An irritant is an agent capable of producing discomfort or pain along the internal lumen of the vein (s 105 INS SOP …
NCCN Clinical Practice Guidelines in Oncology NCCN ...
www2.tri-kobe.orgCarboplatin + albumin-bound paclitaxel + atezolizumab as an "other recommended" treatment option as a category 2A. Nivolumab + ipilimumab as an "other recommended" treatment option as a category 2A. NSCL-J 3 of 4 • The following treatment options added for patients with metastatic squamous cell NSCLC, PD-L1 <1%, and PS 0-1.
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.eupaclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1). Tecentriq, in combination with nab - paclitaxel and carboplatin, is indicated for the first -line treatment of adult patients with metastatic non- squamous NSCLC who do not have EGFR mutant or